Wechselwirkungen · Sildenafil Teva
Sildenafil Teva 25 mg film-coated tablets Sildenafil Teva 50 mg film-coated tablets Sildenafil Teva 100 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 6
HOS-210791 · Präparat HOS-154587
Riociguat: Preclinical studies showed additive systemic blood pressure lowering effect when PDE5 inhibitors were combined with riociguat. In clinical studies, riociguat has been shown to augment the hypotensive effects of PDE5 inhibitors. There was no evidence of favourable clinical effect of the combination in the population studied. Concomitant use of riociguat with PDE5 inhibitors, including sildenafil, is contraindicated (see section 4.3).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): riociguat (HOS-086293)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2022-07-04T14:29:00Z · SHA-256 0b432e138830c0aeb116ef3ec7bfb1d55513ba6e91690f196dc9b46d7cffe7bc · Passage fb207357e01f6963af8ef0ba3724a31dffe7034c79512e41a6f13722046d8352 · Zeichen 5069–5516 im Abschnitt